© 2024 HSP News Service, L.L.C.
In the winter of 2013, my son, Dmitriy, now 26, had a cough that wouldn’t go away. After several rounds of antibiotics failed to halt the persistent problem, a pulmonologist we consulted ordered a chest x-ray, which showed a large tumor lodged between Dmitriy’s lungs. Although the doctor said the...
In a phase I/II study reported in the Journal of Clinical Oncology,1 Nabil Ahmed, MD, MSc, of Baylor College of Medicine, Houston, and colleagues, found that infusion of T cells expressing HER2-specific chimeric antigen receptor (CAR) with a CD28.ζ signaling domain (HER2-CAR T cells) could produce...
Eribulin (Halaven), a cytotoxic agent approved for advanced/metastatic breast cancer, may improve overall survival for patients with two common and difficult-to-treat forms of advanced/metastatic sarcoma, investigators reported at the 2015 ASCO Annual Meeting.1 Eribulin is a microtubule inhibitor...
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to NanoSmart Pharmaceuticals’ novel formulation of dactinomycin for the treatment of Ewing sarcoma, a rare type of childhood bone cancer. The designation was granted on the basis of a plausible hypothesis that the novel ...
The U.S. Food and Drug Administration has approved the novel chemotherapy drug trabectedin (Yondelis) for the treatment of specific soft-tissue sarcomas—liposarcoma and leiomyosarcoma—that are unresectable or metastatic. Trabectedin is a novel marine antineoplastic alkaloid with a unique mechanism ...
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On October 23, 2015, trabectedin (Yondelis) was approved for the...
Led by George Demetri, MD, of Dana-Farber Cancer Institute, Boston, expert medical oncology investigators from leading academic sarcoma centers and Janssen Pharmaceuticals employees performed a phase III trial in order to provide evidence for the U.S. Food and Drug Administration (FDA) approval of...
In a phase III trial reported in the Journal of Clinical Oncology, George D. Demetri, MD, of Harvard Medical School and Dana-Farber Cancer Institute, Boston, and colleagues found that treatment with trabectedin (Yondelis) significantly improved progression-free survival vs dacarbazine in patients...
Sometimes, cancer treatments that initially appear promising begin to lose their effectiveness. This is due to the ability diseases like cancer have to develop resistance to treatments over time and, essentially, outsmart them. But what if there were ways to ensure this didn’t happen? What if...
As reported in the Journal of Clinical Oncology by Weigel et al in the Children’s Oncology Group, a strategy of dose intensification and interval compression, use of the most active agents determined in phase II window studies, and use of irinotecan as a radiation sensitizer has been found to ...
The U.S. Food and Drug Administration today approved the chemotherapy drug trabectedin (Yondelis) for the treatment of specific soft-tissue sarcomas—liposarcoma and leiomyosarcoma—that are unresectable or metastatic. This treatment is approved for patients who previously received...
In a randomized phase IIb trial reported in JAMA Oncology, Chawla et al found that aldoxorubicin—a novel albumin-binding prodrug of doxorubicin—produced longer progression-free survival than doxorubicin as first-line treatment for metastatic or locally advanced unresectable soft-tissue...
In a phase III trial reported in the Journal of Clinical Oncology, Demetri et al found that treatment with trabectedin significantly improved progression-free survival vs dacarbazine in patients with advanced liposarcoma or leiomyosarcoma after prior conventional chemotherapy. Interim analysis of...
In a French phase II trial reported in the Journal of Clinical Oncology, Ray-Coquard et al found no apparent benefit of paclitaxel plus bevacizumab (Avastin) compared with weekly paclitaxel in patients with inoperable locally advanced or metastatic angiosarcoma. Study Details In this...
The FDA has granted Orphan Drug designation to NanoSmart Pharmaceuticals’ novel formulation of dactinomycin for the treatment of Ewing sarcoma, a rare type of childhood bone cancer. The designation was granted on the basis of a plausible hypothesis that the novel formulation, which uses...
In the phase III EURAMOS-1 trial reported in the Journal of Clinical Oncology, Bielack et al found that the addition of postoperative pegylated interferon alfa-2b (Pegintron, Sylatron) to MAP (methotrexate, doxorubicin, and cisplatin) in patients with osteosarcoma showing good histologic response...
Heavily pretreated patients with intermediate- or high-grade liposarcoma or leiomyosarcoma had a 2-month increase in median overall survival when subsequently treated with eribulin (Halaven) rather than the standard drug dacarbazine. “For a disease where so few treatment options exist, a...
Researchers at the University of California (UC) San Diego School of Medicine conducted the first population-based study that characterizes the association and temporal relationship between gastrointestinal stromal tumors (GIST) and other cancers. The results, published by Murphy et al in Cancer,...
The American College of Physicians (ACP) released its clinical advice for cervical cancer screening in asymptomatic, average-risk women 21 years or older. Women at average risk are defined as those with no history of a precancerous lesion (cervical intraepithelial neoplasia grade 2 or a more severe ...
A particular molecular pathway permits stem cells in pediatric bone cancers to grow rapidly and aggressively, according to researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center. These findings were published by Basu-Roy et al in Nature Communications. Study...
In a phase I/II study reported in Journal of Clinical Oncology, Ahmed et al found that infusion of T cells expressing HER2-specific chimeric antigen receptor (CAR) with a CD28.ζ signaling domain (HER2-CAR T cells) could produce persistent CAR T cell levels for ≥ 6 weeks in patients with...
In a phase III NRG Oncology/Gynecologic Oncology Group (GOG) trial reported in the Journal of Clinical Oncology, Hensley et al found no benefit of adding bevacizumab (Avastin) to first-line gemcitabine-docetaxel in patients with metastatic uterine leiomyosarcoma. Study Details In this...
As reported in the Journal of Clinical Oncology by Wang et al, the incidence of late toxicity among patients with extremity soft-tissue sarcoma receiving preoperative image-guided radiotherapy to a reduced target volume in the phase II Radiation Therapy Oncology Group (RTOG) 0630 trial was lower...
Janssen Research & Development, LLC, announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for trabectedin to treat patients with advanced soft-tissue sarcoma, including liposarcoma and leiomyosarcoma subtypes, who have...
In an Italian Sarcoma Group phase II study reported in The Lancet Oncology, Grignani et al found that the combination of sorafenib (Nexavar) and everolimus (Afinitor) was active in unresectable high-grade osteosarcoma progressing after standard treatment, but did not produce the study goal of ≥...
Researchers from the Massachusetts General Hospital (MGH) Cancer Center and Boston University School of Medicine (BUSM) have identified a potential treatment targeting a pathway by which several aggressive tumors maintain their ability to proliferate, according to a study by Flynn et al published...
The genetic abnormality that drives the bone cancer Ewing sarcoma operates through two distinct processes, both activating genes that stimulate tumor growth and suppressing those that should keep cancer from developing. The findings by Riggi et al, published in Cancer Cell, may lead to new...
An international collaboration has identified frequent mutations in two genes that often occur together in Ewing sarcoma and that define a subtype of the cancer associated with reduced survival. The research, conducted by the St. Jude Children’s Research Hospital-Washington University...
Intergroup Rhabdomyosarcoma Study Group (IRSG) studies have shown improved failure-free survival with VAC (vincristine, dactinomycin, and cyclophosphamide) given with a total cumulative cyclophosphamide dose of 26.4 g/m2 compared with VA (vincristine and dactinomycin) in patients with subset 1...
Although low mitotic count, surgery, and disease-free interval of more than 6 months were associated with improved survival in women with recurrent or persistent uterine leiomyosarcoma, only low number of mitoses was identified as an independent predictor of survival post relapse, according to...
There are no large-scale direct comparisons of outcomes with intensity-modulated radiation therapy vs conventional external-beam radiation therapy in patients with soft-tissue sarcoma of the extremity. In a single-institution experience reported in the Journal of Clinical Oncology, Folkert et al at ...
In a phase II study reported in the Journal of Clinical Oncology, Chawla et al found that the combination of a hypoxia-activated alkylating prodrug (TH-302) and doxorubicin was active in first-line treatment of advanced soft-tissue sarcoma. TH-302 is a prodrug of the cytotoxic alkylating agent...
In a European phase III noninferiority trial (Euro-EWING99-R1) reported in the Journal of Clinical Oncology, Le Deley et al found that cyclophosphamide was noninferior in event-free survival vs ifosfamide in combination with vincristine/dactinomycin as consolidation therapy in patients with...
A research collaboration between Dana-Farber Cancer Institute and Brigham and Women’s Hospital has utilized nanomedicine technologies to develop a drug-delivery system that can precisely target and attack cancer cells in the bone, as well as increase bone strength and volume to prevent...
The St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project found mutations in the tumor-suppressor gene TP53 in 90% of osteosarcomas, suggesting the alteration plays a key role early in development of the bone cancer. The study by Chen et al was...
Adjuvant radiation following surgery for soft-tissue sarcoma of the extremities did not lead to a survival benefit and seemed to be associated with some degree of long-term limb complications, according to a presentation at the 2014 Society of Surgical Oncology (SSO) Cancer Symposium in Phoenix...
In the open-label, phase III EORTC 62012 trial reported in The Lancet Oncology, Judson et al found that doxorubicin plus ifosfamide was not associated with any overall survival advantage compared with doxorubicin alone in patients with advanced or metastatic soft-tissue sarcoma. Progression-free...
A new analysis has found that a type of radiation therapy called carbon ion radiotherapy can control cancer growth and prolong survival in patients with spinal tumors. The study, published online in Cancer, indicates that the treatment is a promising alternative for patients whose spinal tumors...
Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) have discovered a novel mechanism responsible for the loss of a critical tumor-suppressor gene in rhabdomyosarcoma and other...
Nearly half the surgical procedures for sarcoma done at 85 academic medical centers were performed by surgeons untrained in oncology, according to national data analyzed by researchers from the University of California Davis Medical Center, Sacramento. Orthopedic oncologists and surgical...
Patients with advanced alveolar soft part sarcoma achieved some control of their disease using the experimental anticancer drug cediranib. The results from this largest clinical trial on alveolar soft part sarcoma to date were published online ahead of print on April 29, 2013, in the Journal of...